In a phase I trial of the EZH2 inhibitor tazemetostat, children with INI1-deficient tumors—including relapsed or refractory malignant rhabdoid tumors, atypical teratoid rhabdoid tumors, epithelioid sarcomas, and poorly differentiated chordomas—responded well to treatment, with some experiencing durable responses.

中文翻译：

---

孩子中的罕见肿瘤可能对Tazemetostat有所反应

在EZH2抑制剂tazemetostat的I期试验中，患有INI1缺陷的儿童-包括复发或难治的恶性横纹肌瘤，非典型性叔状横纹肌瘤，上皮样肉瘤和分化差的脊索瘤-对治疗的反应良好，有些经历了持久的反应。